低级别子宫内膜间质肉瘤:土耳其子宫肉瘤组预后因素与疾病结局分析
本研究为多中心回顾性研究,纳入124例接受根治性手术的低级别子宫内膜间质肉瘤(LGESS)患者。中位随访45.5个月,3年无病生存率(DFS)76.9%、总生存率(OS)93.8%,分期是唯一独立预后因素;在分期≥II患者中,淋巴结清扫与改善DFS相关,辅助化疗与较差DFS和OS相关。
要点
- 分期是LGESS唯一独立预后因素。
- 分期≥II患者中,淋巴结清扫与改善DFS相关。
- 分期≥II患者中,辅助化疗与较差DFS和OS相关。
核心结论
- 在分期≥II的LGESS中,盆腔及腹主动脉旁淋巴结转移风险不可忽视,不应省略淋巴结清扫。
- 淋巴结清扫为子宫外病变患者提供显著DFS获益。
研究设计与样本
- 多中心回顾性研究,共纳入124例接受根治性手术的LGESS患者。
- 排除标准包括:其他浸润性疾病史、新辅助治疗、保留生育功能手术、切片复核后诊断不同。
主要发现
- 全部患者行子宫切除术,96%行双侧输卵管卵巢切除术,65%行淋巴结清扫。
- 81例行淋巴结清扫的患者中12例(14.8%)有淋巴结转移,其中8例(9.8%)有盆腔淋巴结转移,4例(5.6%)为孤立腹主动脉旁淋巴结转移。
- 8例盆腔淋巴结阳性患者中6例(75%)合并腹主动脉旁淋巴结转移。
- 124例中3例(2.4%)原发治疗后为难治性疾病;中位随访45.5个月,121例完全缓解者中27例(22.3%)复发,10例(8.1%)死于疾病。
- 3年DFS为76.9%,3年OS为93.8%;分期是全队列唯一独立预后因素。
关键数值与推荐
- 分期I亚组中无显著预后因素;分期≥II亚组中,淋巴结清扫与改善DFS显著相关,辅助化疗与较差DFS和OS显著相关。
临床怎么用
- 对分期≥II的LGESS,应重视盆腔及腹主动脉旁淋巴结评估,考虑行淋巴结清扫以改善DFS。
- 分期≥II患者辅助化疗与较差结局相关,临床决策需个体化权衡。
局限性
- 回顾性多中心研究设计,可能存在选择偏倚。
- 淋巴结清扫和辅助化疗的关联为观察性结果,不能推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate factors associated with refractory disease, recurrence, or death as well as disease-free survival (DFS) and overall survival (OS) in low-grade endometrial sarcoma (LGESS). METHODS: A multi-institutional, retrospective study was conducted in a total of 124 patients, who received a curative-intent surgery. The exclusion criteria were as follows: i) history of any other invasive disease; ii) neoadjuvant therapy; iii) fertility sparing surgery; iv) a different diagnosis after review of the slides. RESULTS: All patients underwent hysterectomy, 96% had bilateral salpingo-oophorectomy, and 65% had lymphadenectomy. Twelve (14.8%) of 81 patients undergoing lymphadenectomy had lymph node (LN) metastasis. Of those, 8 (9.8%) had pelvic LN metastasis whereas 4 (5.6%) had isolated paraaortic LN metastasis. Six of 8 (75%) patients with positive pelvic LNs had concurrent paraaortic LN metastasis. Among 124 patients, 3 patients (2.4%) had refractory disease following primary therapy. During a median follow-up of 45.5 months, 27 (22.3%) of 121 patients who achieved complete remission after primary therapy developed recurrence, and 10 patients (8.1%) died of disease. The 3-year DFS and OS were 76.9% and 93.8%, respectively. Stage was the sole independent prognostic factor in the whole cohort. When analyzing factors within subgroups of stage I and stage ≥II, there was no significant prognostic factor for stage I; however, lymphadenectomy and adjuvant chemotherapy were significantly associated with disease outcomes for stage ≥II. While lymphadenectomy was related with improved DFS, chemotherapy was associated with poor DFS and OS. CONCLUSION: The risk of LN metastasis at pelvic as well as paraaortic lymphatic basins is not negligible to omit lymphadenectomy in stage ≥II LGESS. Moreover, lymphadenectomy provides significant DFS advantage in patients with extrauterine disease.
引用
- Ayhan A, Toptas T, Oz M, et al. Low-grade endometrial stromal sarcoma: A Turkish uterine sarcoma group study analyzing prognostic factors and disease outcomes. Gynecol Oncol. 2020. PMID: 33375988. doi:10.1016/j.ygyno.2020.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。